ArticlebioRxiv : the preprint server for biology2023
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide.
Jaimie S Gray et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.